Peptide Cargo Nanoparticles for Targeted, Low-Toxicity Cell Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering therapeutic molecules such as proteins, peptides, and nucleic acids into cells face challenges including poor stability, low uptake, and toxicity, limiting their therapeutic potential.
Innovation Solution
Development of cargo delivery complexes and nanoparticles comprising cell-penetrating peptides, including those with polyethylene glycol (PEG) moieties and targeting sequences, to facilitate intracellular delivery of molecules like nucleic acids, proteins, and protein complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral delivery strategies are used, then gene and cellular therapies show promise, but side effects and toxicity occur
Solution Approach 1:
The patent introduces cell-penetrating peptides as intermediary carriers that mediate the delivery of therapeutic cargo molecules into cells without using viral vectors. These peptides facilitate cellular uptake through non-viral mechanisms, thereby achieving therapeutic delivery while avoiding the toxicity and immunogenicity associated with viral delivery systems.
Solution Approach 2:
The patent modifies the chemical and physical parameters of delivery systems by using synthetic peptides with controlled properties (amphipathic structure, specific amino acid compositions, PEGylation) instead of biological viral vectors. This parameter change transforms the delivery mechanism from biological to chemical/physical, reducing toxicity while maintaining delivery efficacy.
2Object-affected harmful factors
If non-viral delivery methods are used, then toxicity is reduced, but delivery efficiency remains insufficient
Solution Approach 1:
The patent employs composite peptide structures combining multiple functional elements: cell-penetrating domains (amphipathic peptides), targeting sequences (RGD, YIGSR), and stabilizing moieties (PEG). This composite approach integrates cell membrane interaction, target recognition, and stability enhancement into a single non-viral delivery system, improving delivery efficiency while maintaining low toxicity.
Solution Approach 2:
The cell-penetrating peptides described in the patent are designed to perform multiple functions simultaneously: facilitating cellular uptake, providing stability in physiological conditions, enabling target-specific delivery through incorporated sequences, and protecting cargo molecules. This multi-functionality allows non-viral systems to achieve viral-level efficiency without the associated toxicity.
3Measurement precision
If larger therapeutic molecules are used, then target specificity is improved, but stability and cellular uptake decrease
Solution Approach 1:
The patent uses cell-penetrating peptides as intermediary carriers that bind to larger therapeutic molecules (proteins, nucleic acids) and facilitate their cellular uptake. These peptide mediators protect the cargo from degradation, enhance stability in physiological environments, and actively promote entry into target cells, thereby compensating for the inherent instability and poor uptake of large therapeutic molecules.
Solution Approach 2:
The patent incorporates specific local structural features into the peptide carriers, including amphipathic regions for membrane interaction, positively charged residues for electrostatic interactions with cell surfaces, and PEGylated segments for steric stabilization. These localized functional regions endow the entire complex with enhanced stability and cellular uptake capabilities while preserving the target specificity of the cargo molecule.
Data Source
AI summary
The present application is directed to cargo delivery complexes for intracellular delivery of a cargo molecule comprising: a first peptide comprising a cell-penetrating peptide (CPP), a second peptide comprising a cell-penetrating peptide, and a cargo molecule. The second peptide comprises a polyethylene glycol (PEG) moiety linked to the second CPP, and the first peptide does not have a PEG moiety. The present application is also directed to a cargo delivery complex comprising a CPP and a cargo molecule wherein the CPP is a retro-inverso peptide. The present application is also directed to a cargo delivery complex comprising a CPP and a cargo molecule wherein the peptide further comprises a targeting sequence selected from the group consisting of GYVSK, GYVS, YIGS and YIGSR. Methods of making and using the cargo delivery complexes are also disclosed.